Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 3
1959 1
1965 2
1966 1
1973 1
2012 1
2016 1
2018 2
2019 1
2020 1
2022 5
2023 1

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.
Morand E, Pike M, Merrill JT, van Vollenhoven R, Werth VP, Hobar C, Delev N, Shah V, Sharkey B, Wegman T, Catlett I, Banerjee S, Singhal S. Morand E, et al. Among authors: delev n. Arthritis Rheumatol. 2023 Feb;75(2):242-252. doi: 10.1002/art.42391. Epub 2022 Nov 11. Arthritis Rheumatol. 2023. PMID: 36369798 Free PMC article. Clinical Trial.
Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus.
Merrill JT, Werth VP, Furie R, van Vollenhoven R, Dörner T, Petronijevic M, Velasco J, Majdan M, Irazoque-Palazuelos F, Weiswasser M, Korish S, Ye Y, Gaudy A, Schafer PH, Liu Z, Agafonova N, Delev N. Merrill JT, et al. Among authors: delev n. N Engl J Med. 2022 Mar 17;386(11):1034-1045. doi: 10.1056/NEJMoa2106535. N Engl J Med. 2022. PMID: 35294813 Clinical Trial.
Biological impact of iberdomide in patients with active systemic lupus erythematosus.
Lipsky PE, Vollenhoven RV, Dörner T, Werth VP, Merrill JT, Furie R, Petronijevic M, Velasco Zamora B, Majdan M, Irazoque-Palazuelos F, Terbrueggen R, Delev N, Weiswasser M, Korish S, Stern M, Hersey S, Ye Y, Gaudy A, Liu Z, Gagnon R, Tang S, Schafer PH. Lipsky PE, et al. Among authors: delev n. Ann Rheum Dis. 2022 Apr 27;81(8):1136-42. doi: 10.1136/annrheumdis-2022-222212. Online ahead of print. Ann Rheum Dis. 2022. PMID: 35477518 Free PMC article.
Ileo-urethroplastica perinealis.
DELEV N. DELEV N. Br J Urol. 1959 Sep;31:327-31. doi: 10.1111/j.1464-410x.1959.tb09426.x. Br J Urol. 1959. PMID: 13815626 No abstract available.
Novel cause of sudden cardiac death: IgG4-related disease.
Holmes BJ, Delev NG, Pasternack GR, Halushka MK. Holmes BJ, et al. Among authors: delev ng. Circulation. 2012 Jun 12;125(23):2956-7. doi: 10.1161/CIRCULATIONAHA.111.061002. Circulation. 2012. PMID: 22689933 No abstract available.
Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies.
Gladman DD, Kavanaugh A, Gómez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, Guerette B, Delev N, Teng L, Edwards CJ, Birbara CA, Mease PJ. Gladman DD, et al. Among authors: delev n. RMD Open. 2018 Jun 27;4(1):e000669. doi: 10.1136/rmdopen-2018-000669. eCollection 2018. RMD Open. 2018. PMID: 30018799 Free PMC article.
19 results